Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000597 | 0.83 | HDAC1 (0.43) | HDAC8HDAC3HDAC6HDAC1HDAC11 | |
| SCHEMBL9093734 | 0.83 | HDAC1 (0.43) | HDAC8HDAC3HDAC6HDAC1HDAC11 | |
| SCHEMBL9000645 | 0.79 | ZDHHC7 (0.45) | HDAC8HDAC3HDAC6HDAC1HDAC11 | |
| SCHEMBL3854654 | 0.78 | ALDH1A1 (0.45) | HDAC8HDAC3HDAC6HDAC1HDAC2 | |
| SCHEMBL27680341 | 0.78 | HTT (0.44) | HDAC8HDAC3HDAC6HDAC1HDAC11 | |
| SCHEMBL28170178 | 0.77 | HTT (0.45) | HDAC8HDAC3HDAC6HDAC1HDAC11 | |
| SCHEMBL9567286 | 0.76 | HDAC1 (0.40) | HDAC8HDAC3HDAC6HDAC1HDAC11 | |
| SCHEMBL1162571 | 0.76 | HDAC2 (0.68) | HDAC8HDAC3HDAC6HDAC1HDAC2 | |
| SCHEMBL13369426 | 0.76 | HDAC2 (0.68) | HDAC8HDAC3HDAC6HDAC1HDAC2 | |
| SCHEMBL20353846 | 0.76 | HDAC8 (0.58) | HDAC8HDAC3HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864246-B2 | Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae | PIERRE FABRE MEDICAMENT (FR) | 2005-03-08 | — | — | US | claimed |
| US-20040127462-A1 | Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae | PIERRE FABRE MEDICAMENT (FR) | 2004-07-01 | — | — | US | claimed |
| US-6864246-B2 | Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae | PIERRE FABRE MEDICAMENT (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20040127462-A1 | Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae | PIERRE FABRE MEDICAMENT (FR) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127462-A1 | Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae | APOB, HDLBP, PCSK9 | HDAC8 954/4885HDAC3 274/4885HDAC6 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.